Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.
NCT ID: NCT00256048
Last Updated: 2017-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2003-05-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study hypothesis is that in patients who fail to establish enteral feeding via the nasogastric route, introduction of nasojejunal feeding will lead to more effective enteral feeding than the current regime involving staged introduction of promotility agents.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study
NCT00163813
Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients
NCT00807287
Comparison of Different Methods of Nasogastric Tube Insertion in Anesthetized and Intubated Patients
NCT02557204
Nasal Bridles and Repeat Endoscopic Procedures for Endoscopic Nasoenteric Tubes
NCT03966157
Effect of Multifunctional Nutrition Tube on Cerebral Small Vessel Disease Patients
NCT06328842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study compares the efficacy of nasojejunal feeding feeding with nasogastric enteral feeding with the addition of promotility agents.
The duration of feeding will be determined by the patients nutritional requirements and their general condition. However the data will be collected for duration of enteral feeding, 28 days or ICU discharge whichever occurs first.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care
Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
No interventions assigned to this group
Nasojejunal Arm
Patient will receive feeding via a nasojejunal feeding tube
Nasojejunal feeding
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nasojejunal feeding
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients commenced on enteral feeding via a nasogastric tube who fail to tolerate gastric feeding due to excessive gastric aspirate volumes.
3. Patients who consent or if the patient is incompetent, the next of kin, who consent, to inclusion in the study.
\-
Exclusion Criteria
2. Patients with known allergy to promotility agents, metoclopramide or erythromycin.
3. Patients with a contra indication to nasojejunal feeding. -
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Melbourne Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Melbourne Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Megan Robertson
Role: PRINCIPAL_INVESTIGATOR
Intensive Care Unit, Royal Melbourne Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensive Care Unit, Royal Melbourne Hospital, Grattan Street
Parkville, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2002.228
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.